Novel investigational therapeutics for panic disorder

Expert Opinion on Investigational Drugs

Volumn 24, Issue 4, 2015, Pages 491-505

  Perna, Giampaolo ^a,b,c   Schruers, Koen ^b,d   Alciati, Alessandra ^a   Caldirola, Daniela ^a  

^a Department of Clinical Neurosciences   (Italy)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Glutamate; Novel drugs; Orexin; Panic disorder

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; ABIO 0801; ALPRAZOLAM; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTALARMIN; ANTIPANIC AGENT; APTIGANEL; ARGININE VASOPRESSINE V1B; ARGIPRESSIN; BUSPIRONE; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DIZOCILPINE; EGLUMETAD; EMAPUNIL; ISOXAZOLINE DERIVATIVE; KETAMINE; LOSARTAN; MAPROTILINE; METABOTROPIC RECEPTOR AGONIST; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE S; SARALASIN; SERTRALINE; SPANTIDE; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VESTIPITANT; VOFOPITANT; ANXIOLYTIC AGENT; NEW DRUG;

ELECTROSTIMULATION; EXPERIMENTAL MODEL; HUMAN; HYPOTHALAMUS; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; DISEASE MODEL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PANIC DISORDER; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR TARGETED THERAPY; PANIC DISORDER;

EID: 84924726421     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.996286     Document Type: Review

References (100)

1. Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21(3):169-84
2. National Guideline C. Practice guideline for the treatment of patients with panic disorder. Available from: http://www. guideline.gov/content.aspx?id=14230 [Cited 15 October 2014]
3. Farach FJ, Pruitt LD, Jun JJ, et al. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord 2012;26(8):833-43
4. Perna G, Guerriero G, Caldirola D. Emerging drugs for panic disorder. Expert Opin Emerg Drugs 2011;16(4):631-45
5. Perna G. Understanding anxiety disorders: the psychology and the psychopathology of defence mechanisms against threats. Riv Psichiatr 2013;48(1):73-5
6. Johnson PL, Federici LM, Shekhar A. Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks. Neurosci Biobehav Rev 2014;46P3:429-54
7. Freire RC, Perna G, Nardi AE. Panic disorder respiratory subtype: psychopathology, laboratory challenge tests, and response to treatment. Harv Rev Psychiatry 2010;18(4):220-9
8. Roberson-Nay R, Kendler KS. Panic disorder and its subtypes: a comprehensive analysis of panic symptom heterogeneity using epidemiological and treatment seeking samples. Psychol Med 2011;41(11):2411-21
9. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 1993;50(4):306-17
10. Preter M, Klein DF. Lifelong opioidergic vulnerability through early life separation: a recent extension of the false suffocation alarm theory of panic disorder. Neurosci Biobehav Rev 2014;46P3:345-51
11. Perna G, Caldirola D, Bellodi L. Panic disorder: from respiration to the homeostatic brain. Acta Neuropsychiatr 2004;16(2):57-67
12. Esquivel G, Schruers KR, Maddock RJ, et al. Acids in the brain: a factor in panic? J Psychopharmacol 2010;24(5):639-47
13. Graeff FG, Del-Ben CM. Neurobiology of panic disorder: from animal models to brain neuroimaging. Neurosci Biobehav Rev 2008;32(7):1326-35
14. Canteras NS, Graeff FG. Executive and modulatory neural circuits of defensive reactions: implications for panic disorder. Neurosci Biobehav Rev 2014;46P3:352-64
15. Perna G, Guerriero G, Brambilla P, et al. Panic and the brainstem: clues from neuroimaging studies. CNS Neurol Disord Drug Targets 2014;13(6):1049-56
16. Goossens L, Leibold N, Peeters R, et al. Brainstem response to hypercapnia: a symptom provocation study into the pathophysiology of panic disorder. J Psychopharmacol 2014;28(5):449-56
17. Paul ED, Johnson PL, Shekhar A, et al. The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic. Neurosci Biobehav Rev 2014;46P3:379-96
18. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157(4):493-505
19. Feinstein JS, Buzza C, Hurlemann R, et al. Fear and panic in humans with bilateral amygdala damage. Nat Neurosci 2013;16(3):270-2
20. Moreira FA, Gobira PH, Viana TG, et al. Modeling panic disorder in rodents. Cell Tissue Res 2013;354(1):119-25
21. Andrews NA, Papakosta M, Barnes NM. Discovery of novel anxiolytic agents-the trials and tribulations of pre-clinical models of anxiety. Neurobiol Dis 2014;61:72-8
22. Johnson PL, Shekhar A. An animal model of panic vulnerability with chronic disinhibition of the dorsomedial/perifornical hypothalamus. Physiol Behav 2012;107(5):686-98
23. Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med 2010;16(1):111-15
24. Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000;39(7):1139-46
25. Johnson AK, Gross PM. Sensory circumventricular organs and brain homeostatic pathways. FASEB J 1993;7(8):678-86
26. Johnson PL, Truitt WA, Fitz SD, et al. Neural pathways underlying lactateinduced panic. Neuropsychopharmacology 2008;33(9):2093-107
27. Johnson P, Lowry C, Truitt W, et al. Disruption of GABAergic tone in the dorsomedial hypothalamus attenuates responses in a subset of serotonergic neurons in the dorsal raphe nucleus following lactate-induced panic. J Psychopharmacol 2008;22(6):642-52
28. Zangrossi H Jr, Graeff FG. Serotonin in anxiety and panic: contributions of the elevated T-maze. Neurosci Biobehav Rev 2014;46P3:397-406
29. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, et al. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 2012;100(4):752-74
30. Harvey BH, Shahid M. Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. Pharmacol Biochem Behav 2012;100(4):775-800
31. Long Z, Medlock C, Dzemidzic M, et al. Decreased GABA levels in anterior cingulate cortex/medial prefrontal cortex in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2013;44:131-5
32. Hettema JM, An SS, Neale MC, et al. Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Mol Psychiatry 2006;11(8):752-62
33. Johnson PL, Fitz SD, Engleman EA, et al. Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. J Psychopharmacol 2013;27(2):152-61
34. Johnson PL, Shekhar A. Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors. J Neurosci 2006;26(26):7093-104
35. Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 2014;23(2):243-54
36. Schoepp DD, Wright RA, Levine LR, et al. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003;6(3):189-97
37. Bergink V, Westenberg HG. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol 2005;20(6):291-3
38. Rorick-Kehn LM, Perkins EJ, Knitowski KM, et al. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 2006;316(2):905-13
39. Kellner M, Muhtz C, Stark K, et al. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 2005;179(1):310-15
40. Nattie E, Li A. Respiration and autonomic regulation and orexin. Prog Brain Res 2012;198:25-46
41. Johnson PL, Samuels BC, Fitz SD, et al. Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacology 2012;37(8):1911-22
42. Johnson PL, Samuels BC, Fitz SD, et al. Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Physiol Behav 2012;107(5):733-42
43. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003;54(2):96-104
44. Johnson PL, Molosh A, Fitz SD, et al. Orexin, stress, and anxiety/panic states. Prog Brain Res 2012;198:133-61
45. Silva MS, Pereira BA, Cespedes IC, et al. Dorsomedial hypothalamus CRF type 1 receptors selectively modulate inhibitory avoidance responses in the elevated T-maze. Behav Brain Res 2014;271:249-57
46. Bailey JE, Papadopoulos A, Diaper A, et al. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol 2011;25(9):1199-206
47. Keck ME, Kern N, Erhardt A, et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B(7):1196-204
48. Ishitobi Y, Nakayama S, Yamaguchi K, et al. Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 2012;159B(4):429-36
49. de Oliveira Sergio T, Spiacci A Jr, Zangrossi H Jr. Effects of dorsal periaqueductal gray CRF1-and CRF2-receptor stimulation in animal models of panic. Psychoneuroendocrinology 2014;49:321-30
50. Shekhar A, Johnson PL, Fitz SD, et al. A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactateinduced acute panic-like responses. Int J Neuropsychopharmacol 2011;14(3):355-65
51. Welkowitz LA, Papp L, Martinez J, et al. Instructional set and physiological response to CO2 inhalation. Am J Psychiatry 1999;156(5):745-8
52. Colasanti A, Esquivel G, Schruers KJ, et al. On the psychotropic effects of carbon dioxide. Curr Pharm Des 2012;18(35):5627-37
53. Shekhar A, Johnson PL, Sajdyk TJ, et al. Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J Neurosci 2006;26(36):9205-15
54. Grassi M, Caldirola D, Vanni G, et al. Baseline respiratory parameters in panic disorder: a meta-analysis. J Affect Disord 2013;146(2):158-73
55. Grassi M, Caldirola D, Di Chiaro NV, et al. Are respiratory abnormalities specific for panic disorder? A meta-analysis. Neuropsychobiology 2014;70(1):52-60
56. Olsson M, Annerbrink K, Hedner J, et al. Intracerebroventricular administration of the angiotensin II receptor antagonist saralasin reduces respiratory rate and tidal volume variability in freely moving Wistar rats. Psychoneuroendocrinology 2004;29(1):107-12
57. Gulec-Yilmaz S, Gulec H, Dalan AB, et al. The relationship between ACE polymorphism and panic disorder. In Vivo 2014;28(5):885-9
58. Bandelow B, Saleh K, Pauls J, et al. Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: a genderspecific effect? World J Biol Psychiatry 2010;11(1):66-70
59. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7(5):438-55
60. Moreira FA, Aguiar DC, Terzian AL, et al. Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 2012;204:186-92
61. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81(2):331-42
62. Rubino T, Realini N, Castiglioni C, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008;18(6):1292-301
63. Moreira FA, Aguiar DC, Resstel LB, et al. Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. J Psychopharmacol 2012;26(1):40-55
64. Soares Vde P, Campos AC, Bortoli VC, et al. Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 2010;213(2):225-9
65. Campos AC, de Paula Soares V, Carvalho MC, et al. Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology (Berl) 2013;226(1):13-24
66. Casarotto PC, Terzian AL, Aguiar DC, et al. Opposing roles for cannabinoid receptor type-1 (CB(1)) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats. Neuropsychopharmacology 2012;37(2):478-86
67. Almeida-Santos AF, Moreira FA, Guimaraes FS, et al. Role of TRPV1 receptors on panic-like behaviors mediated by the dorsolateral periaqueductal gray in rats. Pharmacol Biochem Behav 2013;105:166-72
68. Gobira PH, Aguiar DC, Moreira FA. Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze. Pharmacol Biochem Behav 2013;110:33-9
69. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318(1):304-11
70. Micale V, Cristino L, Tamburella A, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009;34(3):593-606
71. John CS, Currie PJ. N-arachidonoyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze. Behav Brain Res 2012;233(2):382-8
72. Nothdurfter C, Rammes G, Baghai TC, et al. Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J Neuroendocrinol 2012;24(1):82-92
73. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepinelike side effects. Science 2009;325(5939):490-3
74. Pini S, Martini C, Abelli M, et al. Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psychopharmacology (Berl) 2005;181(2):407-11
75. Brambilla F, Biggio G, Pisu MG, et al. Neurosteroid secretion in panic disorder. Psychiatry Res 2003;118(2):107-16
76. Strohle A, Romeo E, di Michele F, et al. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry 2002;159(1):145-7
77. Perna G, Brambilla F, Arancio C, et al. Menstrual cycle-related sensitivity to 35% CO2 in panic patients. Biol Psychiatry 1995;37(8):528-32
78. Strohle A, Romeo E, di Michele F, et al. Induced panic attacks shift gammaaminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003;60(2):161-8
79. Quast C, Reif A, Bruckl T, et al. Gender-specific association of variants in the Akr1c1 gene with dimensional anxiety in patients with panic disorder: additional evidence for the importance of neurosteroids in anxiety? Depress Anxiety 2014;31(10):843-50
80. Poma SZ, Merlo-Pich E, Bettica P, et al. Anxiolytic effects of vestipitant in a subgroup of healthy volunteers known to be sensitive to CO2 challenge. J Psychopharmacol 2014;28(5):491-7
81. Fujimura Y, Yasuno F, Farris A, et al. Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry 2009;66(1):94-7
82. Broiz AC, Bassi GS, De Souza Silva MA, et al. Effects of neurokinin-1 and 3-receptor antagonists on the defensive behavior induced by electrical stimulation of the dorsal periaqueductal gray. Neuroscience 2012;201:134-45
83. Iijima M, Yoshimizu T, Shimazaki T, et al. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325. Br J Pharmacol 2014;171(14):3511-25
84. van Duinen MA, Schruers KR, Maes M, et al. CO2 challenge induced HPA axis activation in panic. Int J Neuropsychopharmacol 2007;10(6):797-804
85. Battaglia M, Ogliari A. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev 2005;29(1):169-79
86. Reinscheid RK, Xu YL, Okamura N, et al. Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther 2005;315(3):1338-45
87. Pulga A, Ruzza C, Rizzi A, et al. Anxiolytic-and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. Eur J Neurosci 2012;36(11):3531-7
88. Domschke K, Reif A, Weber H, et al. Neuropeptide S receptor gene-converging evidence for a role in panic disorder. Mol Psychiatry 2011;16(9):938-48
89. Anderer P, Saletu B, Wolzt M, et al. Double-blind, placebo-controlled, multiple-ascending-dose study on the effects of ABIO-08/01, a novel anxiolytic drug, on perception and cognition, utilizing event-related potential mapping and low-resolution brain electromagnetic tomography. Hum Psychopharmacol 2008;23(3):243-54
90. PHARMA A. A multicenter, parallelgroup, double-blind, randomized, placebocontrolled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in patients suffering from panic disorder. In: EudraCT [Internet]. European Medicines Agency (UK), London; 2007. EudraCT Number: 2007-001060-80 Available from: https://www. clinicaltrialsregister.eu/ctr-search/trial/2007-001060-80/IT [Cited 15 October 2014]
91. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008;83(2):227-30
92. Schruers K, Esquivel G, van Duinen M, et al. Genetic moderation of CO2-induced fear by 5-HTTLPR genotype. J Psychopharmacol 2011;25(1):37-42
93. Leibold NK, Viechtbauer W, Goossens L, et al. Carbon dioxide inhalation as a human experimental model of panic: the relationship between emotions and cardiovascular physiology. Biol Psychol 2013;94(2):331-40
94. Wemmie JA. Neurobiology of panic and pH chemosensation in the brain. Dialogues Clin Neurosci 2011;13(4):475-83
95. D'Amato FR, Zanettini C, Lampis V, et al. Unstable maternal environment, separation anxiety, and heightened CO2 sensitivity induced by gene-by-environment interplay. PLoS One 2011;6(4):e18637
96. Perna G, Favaron E, Di Bella D, et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005;30(12):2230-5
97. Ishiguro S, Watanabe T, Ueda M, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2011;67(12):1213-21
98. Woo JM, Yoon KS, Choi YH, et al. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res 2004;38(4):365-70
99. Battaglia M, Bertella S, Ogliari A, et al. Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry 2001;58(2):114-19
100. Craske MG. The R-DoC initiative: science and practice. Depress Anxiety 2012;29(4):253-6